Intas’ Accord Pens $165m Deal To Bring In Bio-Thera’s Golimumab In The US
Accord Continues Building Presence Through Deals; Follows EMA Acceptance For Biosimilar
Having recently acquired Coherus’ biosimilar pegfilgrastim franchise in the US and welcomed FDA approval for its partnered ustekinumab biosimilar, Accord Biopharma is again spending big to flesh out its US biosimilar pipeline.
